



Toxicological Profile for Aldrin and Dieldrin

June 2022



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
June 2022	Final toxicological profile released
July 2021	Draft for public comment toxicological profile released
September 2002	Final toxicological profile released
April 1993	Final toxicological profile released
December 1989	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Carolyn Harper, Ph.D. (Lead)
Sam Keith, M.S., C.H.P.

David W. Wohlers, Ph.D.
Mario Citra, Ph.D.
Julie Klotzbach, Ph.D.
Savannah Sierco, M.S.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA/Office of Water.

PEER REVIEWERS

1. David C. Dorman, DVM, PhD, DABVT, DABT; Professor of Toxicology; North Carolina State University- College of Veterinary Medicine; Fulbright- Saastamoinen Foundation Fulbright Scholar; University of Eastern Finland – Kuopio
2. James Klaunig, PhD; Professor and Director of Toxicology; Indiana University School of Medicine; Indianapolis, Indiana
3. Ivan Rusyn, MD, PhD; Professor and Chair; Department of Veterinary Integrative Biosciences; College of Vet Medicine & Biomedical Sciences; Texas A&M University; College Station, Texas

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS	vii
LIST OF FIGURES	ix
LIST OF TABLES	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	1
1.3 MINIMAL RISK LEVELS (MRLs)	5
CHAPTER 2. HEALTH EFFECTS	9
2.1 INTRODUCTION	9
2.2 DEATH	44
2.3 BODY WEIGHT	46
2.4 RESPIRATORY	47
2.5 CARDIOVASCULAR	48
2.6 GASTROINTESTINAL	50
2.7 HEMATOLOGICAL	50
2.8 MUSCULOSKELETAL	52
2.9 HEPATIC	52
2.10 RENAL	56
2.11 DERMAL	57
2.12 OCULAR	58
2.13 ENDOCRINE	59
2.14 IMMUNOLOGICAL	59
2.15 NEUROLOGICAL	61
2.16 REPRODUCTIVE	68
2.17 DEVELOPMENTAL	69
2.18 OTHER NONCANCER	73
2.19 CANCER	73
2.20 GENOTOXICITY	82
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	89
3.1 TOXICOKINETICS	89
3.1.1 Absorption	89
3.1.2 Distribution	90
3.1.3 Metabolism	94
3.1.4 Excretion	96
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	98
3.1.6 Animal-to-Human Extrapolations	98
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	99
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	103
3.3.1 Biomarkers of Exposure	104

3.3.2	Biomarkers of Effect	105
3.4	INTERACTIONS WITH OTHER CHEMICALS	106
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		108
4.1	CHEMICAL IDENTITY	108
4.2	PHYSICAL AND CHEMICAL PROPERTIES	108
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		110
5.1	OVERVIEW	110
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	112
5.2.1	Production	112
5.2.2	Import/Export.....	113
5.2.3	Use	114
5.2.4	Disposal.....	115
5.3	RELEASES TO THE ENVIRONMENT.....	115
5.3.1	Air	116
5.3.2	Water.....	117
5.3.3	Soil	117
5.4	ENVIRONMENTAL FATE	118
5.4.1	Transport and Partitioning.....	118
5.4.2	Transformation and Degradation	123
5.5	LEVELS IN THE ENVIRONMENT.....	128
5.5.1	Air	129
5.5.2	Water.....	132
5.5.3	Sediment and Soil	134
5.5.4	Other Media	136
5.6	GENERAL POPULATION EXPOSURE.....	140
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	150
CHAPTER 6. ADEQUACY OF THE DATABASE.....		152
6.1	INFORMATION ON HEALTH EFFECTS.....	152
6.2	IDENTIFICATION OF DATA NEEDS	152
6.3	ONGOING STUDIES.....	164
CHAPTER 7. REGULATIONS AND GUIDELINES		166
CHAPTER 8. REFERENCES		169
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR ALDRIN/DIELDRIN	B-1
APPENDIX C.	FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR ALDRIN/DIELDRIN.....	C-1
APPENDIX D.	USER'S GUIDE.....	D-1
APPENDIX E.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS	E-1
APPENDIX F.	GLOSSARY	F-1
APPENDIX G.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Oral Exposure to Aldrin	3
1-2. Health Effects Found in Animals Following Oral Exposure to Dieldrin.....	4
1-3. Summary of Sensitive Targets of Aldrin – Oral	6
1-4. Summary of Sensitive Targets of Dieldrin – Oral	7
2-1. Overview of the Number of Studies Examining Aldrin Health Effects	12
2-2. Overview of the Number of Studies Examining Dieldrin Health Effects	13
2-3. Levels of Significant Exposure to Aldrin – Oral	21
2-4. Levels of Significant Exposure to Dieldrin – Oral	38
3-1. Proposed Metabolic Pathway for Aldrin and Dieldrin	94
5-1. Number of NPL Sites with Aldrin Contamination	110
5-2. Number of NPL Sites with Dieldrin Contamination	111
5-3. Aldrin and Dieldrin Degradation.....	124
6-1. Summary of Existing Health Effects Studies on Aldrin By Route and Endpoint.....	153
6-2. Summary of Existing Health Effects Studies on Dieldrin By Route and Endpoint.....	154

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Aldrin.....	8
1-2. Minimal Risk Levels (MRLs) for Dieldrin.....	8
2-1. Levels of Significant Exposure to Aldrin – Oral	14
2-2. Levels of Significant Exposure to Dieldrin – Oral	25
2-3. Summary of Epidemiological Studies Evaluating Possible Associations between Self- Reported Aldrin or Dieldrin Use and Risk of Selected Cancer Types	76
2-4. Summary of Epidemiological Studies Evaluating Possible Associations between Dieldrin Levels in Blood or Adipose Tissue and Risk of Selected Cancer Types.....	78
2-5. Genotoxicity of Aldrin <i>In Vivo</i>	83
2-6. Genotoxicity of Aldrin <i>In Vitro</i>	83
2-7. Genotoxicity of Dieldrin <i>In Vivo</i>	85
2-8. Genotoxicity of Dieldrin <i>In Vitro</i>	85
4-1. Chemical Identity of Aldrin and Dieldrin.....	108
4-2. Physical and Chemical Properties of Aldrin and Dieldrin.....	108
5-1. Facilities that Produce, Process, or Use Aldrin	112
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Aldrin	116
5-3. Bioconcentration Factors in Two Species of Freshwater Fish.....	120
5-4. Lowest Limit of Detection Based on Standards	128
5-5. Example of Environmental Levels of Aldrin/Dieldrin at Non-NPL Locations	128
5-6. Aldrin and Dieldrin Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	129
5-7. Selected Percentiles of Lipid Adjusted Serum Concentrations in ng/mL (ppb) of Dieldrin for the U.S. Population Aged 12 Years and Older	141
5-8. Dieldrin Residues in Adult Components (1980–1982).....	144
5-9. Calculated Dietary Intakes ($\mu\text{g}/\text{kg}$ of Body Weight/Day) of Dieldrin for Three Population Groups	150
6-1. Ongoing Studies on Dieldrin	165
7-1. Regulations and Guidelines Applicable to Aldrin/Dieldrin.....	166